nach oben

Hepatology International

Erschienen in:

01.09.2010 | Original Article

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma

verfasst von: Pisit Tangkijvanich, Pattaratida Sa-nguanmoo, Varocha Mahachai, Apiradee Theamboonlers, Yong Poovorawan

Erschienen in: Hepatology International | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the sequence variations in the enhancer II (EnhII)/basal core promotor (BCP)/precore (PC) and X genes of hepatitis B virus (HBV) in Thai patients with hepatocellular carcinoma (HCC) by conducting a cross-sectional case–control study.

Methods

As much as 60 patients with HCC and 60 patients without HCC, who were matched for sex, age, hepatitis B e antigen (HBeAg) status, and HBV genotype, were included. Viral mutations in the EnhII/BCP/PC and X regions were characterized by direct sequencing in serum samples.

Results

The prevalence of T1753C/A, A1762T/G1764A and G1899A mutations were significantly higher in the HCC group compared to the non-HCC group (43.3 vs. 23.3%, P = 0.02; 88.3 vs. 53.0%, P < 0.001; and 35.0 vs. 8.3%, P = 0.001, respectively). No significant difference between groups was found with respect to G1613A, C1653T, C1766T/T1768A, A1846T/C, T1858C, and G1896A mutations. By multiple logistic regression analysis, the presence of cirrhosis, A1762T/G1764A and G1899A mutations were independently associated with the risk of HCC.

Conclusion

These data suggested that A1762T/G1764A and G1899A mutations were associated with the development of HCC in Thai patients.

Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118–1129CrossRefPubMed

Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294–S308CrossRefPubMed

Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine 2005;23:2409–2423CrossRefPubMed

Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007;127:164–176CrossRefPubMed

Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004;8:321–352CrossRefPubMed

Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52–61CrossRefPubMed

Chen CH, Changchien CS, Lee CM, Hung CH, Hu TH, Wang JH, et al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case–control study. J Infect Dis 2008;198:1634–1642CrossRefPubMed

Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327–334CrossRefPubMed

Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007;27:1356–1363CrossRefPubMed

10.

Shinkai N, Tanaka Y, Ito K, Mukaide M, Hasegawa I, Asahina Y, et al. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol 2007;45:3191–3197CrossRefPubMed

11.

Tanaka Y, Mukaide M, Orito E, Yuen MF, Ito K, Kurbanov F, et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006;45:646–653CrossRefPubMed

12.

Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008;57:98–102CrossRefPubMed

13.

Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001;36:651–660CrossRefPubMed

14.

Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006;97:977–983CrossRefPubMed

15.

Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, et al. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol 2006;45:805–812CrossRefPubMed

16.

Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 2000;19:5213–5220CrossRefPubMed

17.

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005;42:1208–1236

18.

Suwannakarn K, Tangkijvanich P, Thawornsuk N, Theamboonlers A, Tharmaphornpilas P, Yoocharoen P, et al. Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol Res 2008;38:244–251CrossRefPubMed

19.

Tangkijvanich P, Mahachai V, Komolmit P, Fongsarun J, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. World J Gastroenterol 2005;11:2238–2243PubMed

20.

Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57:91–97CrossRefPubMed

21.

Kim JK, Chang HY, Lee JM, Baatarkhuu O, Yoon YJ, Park JY, et al. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol 2009;81:1002–1008CrossRefPubMed

22.

Kuang SY, Jackson PE, Wang JB, Lu PX, Munoz A, Qian GS, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA 2004;101:3575–3580CrossRefPubMed

23.

Takahashi K, Ohta Y, Kanai K, Akahane Y, Iwasa Y, Hino K, et al. Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch Virol 1999;144:1299–1308CrossRefPubMed

24.

Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134–1143CrossRefPubMed

25.

Song LH, Duy DN, Binh VQ, Luty AJ, Kremsner PG, Bock CT. Low frequency of mutations in the X gene, core promoter and precore region of hepatitis B virus infected Vietnamese. J Viral Hepat 2005;12:160–167CrossRefPubMed

26.

Minami M, Poussin K, Kew M, Okanoue T, Brechot C, Paterlini P. Precore/core mutations of hepatitis B virus in hepatocellular carcinomas developed on noncirrhotic livers. Gastroenterology 1996;111:691–700CrossRefPubMed

27.

Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006;130:1153–1168CrossRefPubMed

28.

Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, et al. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol 2008;103:2254–2262CrossRefPubMed

29.

Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037–1044CrossRefPubMed

30.

Malmassari SL, Deng Q, Fontaine H, Houitte D, Rimlinger F, Thiers V, et al. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology 2007;45:1199–1209CrossRefPubMed

31.

Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007;26:2166–2176CrossRefPubMed

32.

Koike K. Hepatitis B virus X gene is implicated in liver carcinogenesis. Cancer Lett 2009;286:60–68

33.

Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, et al. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009;125:621–629CrossRefPubMed

34.

Kim HJ, Park JH, Jee Y, Lee SA, Kim H, Song BC, et al. Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. J Med Virol 2008;80:1337–1343CrossRefPubMed

Titel: A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma
verfasst von: Pisit Tangkijvanich
Pattaratida Sa-nguanmoo
Varocha Mahachai
Apiradee Theamboonlers
Yong Poovorawan
Publikationsdatum: 01.09.2010
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe 3/2010
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-010-9197-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein

Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis)

Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma

Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B

Spontaneous regression of a solitary necrotic nodule of the liver